The new company will develop microbiome diagnostics for multiple indications including inflammatory bowel disease and liver disorders.
The companies will discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules for cancer.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.